New Drugs and Regulation · us
Lipid-lowering RNA therapy moves toward an expanded indication: plozasiran enters FDA’s staged review pilot
Arrowhead expects to submit a supplemental application for severe hypertriglyceridemia before year-end, seeking an earlier review decision through staged submission. This development shortens the potential waiting time; the expanded indication still requires an efficacy and safety review.
For patients with severe hypertriglyceridemia, the threats posed by elevated blood lipids include acute pancreatitis that may recur and require hospitalization. Plozasiran, an RNA therapy developed for these patients, has now gained access to a pathway that could accelerate review. However, a formal application and review still need to be completed before its use can be expanded.
Arrowhead Pharmaceuticals announced on October 7 that the U.S. Food and Drug Administration (FDA) had agreed to include its planned supplemental new drug application for plozasiran in the Split Real-Time Application Review (STAR) pilot program. Both the company announcement and the same-day Business Wire press release republished by AOL stated that the application is still expected to be submitted before the end of 2026. This announcement does not mean that the severe hypertriglyceridemia indication has been approved.
Plozasiran uses RNA interference to suppress the liver’s production of apolipoprotein C-III (APOC3). This protein slows the breakdown and clearance of triglycerides, making reduced production one approach to improving blood lipid levels. The company said the drug is currently approved under the brand name REDEMPLO in the United States and elsewhere to reduce triglycerides in adults with familial chylomicronemia syndrome, alongside dietary management. The planned application seeks to extend treatment to a broader population of patients with severe hypertriglyceridemia.
STAR is designed to allow review work to begin earlier. According to the FDA, application materials are submitted in two parts, usually about two months apart. Reviewers can begin their analysis once they receive the complete first part. The formal review clock starts only after the second part supplies the final clinical study reports and integrated analyses. This arrangement allows some data processing and preparation of subsequent documents to proceed in parallel.
Arrowhead said participation in STAR provides a six-month priority review, compared with ten months for a standard review, and that the FDA may reach a decision at least one month before the priority review target date. However, these timelines are review targets, not promises of an approval date. The FDA also explicitly states that entry into STAR guarantees neither a faster review nor approval of the application.
This arrangement also preserves a resource the company can use in the future. Because participation in STAR does not require a priority review voucher, Arrowhead can retain the voucher it purchased in August 2026. The company said it could use the voucher for another application in the future or sell it for cash. For this application to expand the indication, access to an accelerated review pathway therefore does not require using that voucher.
Eligibility for STAR includes clinical evidence showing that a drug may offer a substantial improvement over existing therapies on clinically meaningful measures. However, this announcement focuses on the review process and does not provide complete clinical data sufficient to reassess benefits and risks. The key questions ahead are whether the company can complete its submission on schedule and how the FDA, after reviewing the full evidence, will determine the eligible patient population and conditions of use.